Alembic Pharmaceuticals Ltd receives USFDA final approval for generic Binimetinib Tablets, with 180-day exclusivity eligibility
- Approved strengths: 15 mg and 45 mg; therapeutically equivalent to Mektovi.
- Used with encorafenib for specified patients with BRAF-mutated melanoma and metastatic non-small cell lung cancer.
- IQVIA estimates US sales of US$282 million for the 12 months ended September 2026.
